ASCO 2022 Prostate Cancer - Results from #40

Viewing 41-60 of 82 articles

ASCO 2022: Targeting B7-H3 in Prostate Cancer: Phase 2 Trial in Localized Prostate Cancer Using the Anti-B7-H3 Antibody Enoblituzumab, with Biomarker Correlatives

ASCO 2022: Tolerability of Abiraterone Combined with Olaparib in Patients with mCRPC: Further Results from the Phase III PROpel Trial

ASCO 2022: Influence of Darolutamide on Cabazitaxel Systemic Exposure

ASCO 2022: Health-Related Quality of Life and Pain in the MAGNITUDE Study of Niraparib With Abiraterone Acetate and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Gene Alterations

ASCO 2022: Tolerability of [177Lu]Lu-PSMA-617 By Treatment Exposure in Patients With Metastatic Castration-Resistant Prostate Cancer: A VISION Study Subgroup Analysis

ASCO 2022: Phase 1 Study of JNJ-69086420, An Actinium-225-Labeled Antibody Targeting Human Kallikrein-2, for Advanced Prostate Cancer

ASCO 2022: Overall Survival and Biomarker Results From Combat: A Phase 2 Study of Bipolar Androgen Therapy Plus Nivolumab for Patients With Metastatic Castrate-Resistant Prostate Cancer

ASCO 2022: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP1801)—A Randomized Phase 3, Double-Blind, Placebo-Controlled Trial of Adding Darolutamide to ADT and Definitive

ASCO 2022: Disparities in Delayed Diagnosis, Access to Treatment, and Treatment Delays Among Hispanic Men With Metastatic Prostate Cancer

ASCO 2022: Access to Definitive Treatment and Survival for Intermediate-Risk and High-Risk Prostate Cancer at Hospital Systems Serving Health Disparity Populations

ASCO 2022: Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial PSMA SRT

ASCO 2022: Genomic Aberrations Associated with Overall Survival in mCSPC Treated with Apalutamide or Placebo + ADT in TITAN

ASCO 2022: Feasibility of a Novel Wrist-Worn Thermal Device for Management of Vasomotor Symptoms in Patients with Prostate Cancer

ASCO 2022: Clinical Outcomes and Safety of Enzalutamide + ADT in mHSPC in Patients Aged 75 and ≥ 75 Years: ARCHES Post Hoc Analysis

ASCO 2022: Association of RB1 Mutational Status With Overall Genomic Landscape in Neuroendocrine Prostate Cancer

ASCO 2022: Association of PSA Response and Overall Survival in Patients with mHSPC from the Phase 3 ARASENS Trial

ASCO 2022: Outcome of Patients With PSMA PET/CT Screen Failure by VISION Criteria and Treated With 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

ASCO 2022: Circulating Tumour Cells and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 Plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

ASCO 2022: A Phase III Double Blinded Study of Early Intervention After Radical Prostatectomy with ADT with Darolutamide Versus Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

ASCO 2022: Olaparib Plus Abiraterone As First-Line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: Pharmacokinetics Data From the PROpel Trial

1
2
3
4
5